ACTG 336: NITAZOXANIDE FOR PERSONS W/ AIDS & CRYPTOSPORIDIOSIS

ACTG 336：硝唑尼特用于艾滋病患者

• 批准号: 6263625
• 负责人: ROB R MACGREGOR
• 金额: $ 2.51万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263625
• 关键词: AIDS therapy; HIV infections; antiprotozoal agents; clinical research; cryptosporidiosis; dosage; human subject; human therapy evaluation; microorganism disease chemotherapy; placebos; thiazoles

This is a randomized, double-blind, placebo-controlled trial with twenty-four week maintenance suppression at two different doses for responders. Sixty subjects with cryptosporidiosis only will be enrolled. The primary objective is to determine the frequency of complete, marked, and partial clinical responses in subjects with cryptosporidiosis treated with six weeks of NTZ versus placebo subjects at Day 21.

这是一项随机，双盲的，安慰剂对照试验，二十四周的维护抑制作用，两种不同的剂量。 只有60名隐孢子虫病的受试者才会招募。 主要目的是确定在第21天用六周的NTZ与安慰剂受试者治疗的隐孢子虫病受试者​​的完整，标记和部分临床反应的频率。